Apellis Pharmaceuticals (APLS) Receives a Buy from Stifel Nicolaus


Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Apellis Pharmaceuticals (APLS) today. The company’s shares closed last Monday at $47.20.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 7.2% and a 44.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Phasebio Pharmaceuticals, and Madrigal Pharmaceuticals.

Apellis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $76.54, representing a 62.2% upside. In a report issued on May 17, Oppenheimer also maintained a Buy rating on the stock with a $67.00 price target.

See today’s analyst top recommended stocks >>

Based on Apellis Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $184 million. In comparison, last year the company had a GAAP net loss of $169 million.

Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts